157 related articles for article (PubMed ID: 11242324)
1. From clinical trials to real-world practice: use of atypical antipsychotic medication nationally in the Department of Veterans Affairs.
Rosenheck R; Leslie D; Sernyak M
Med Care; 2001 Mar; 39(3):302-8. PubMed ID: 11242324
[TBL] [Abstract][Full Text] [Related]
2. The effect of institutional fiscal stress on the use of atypical antipsychotic medications in the treatment of schizophrenia.
Leslie DL; Rosenheck R
J Nerv Ment Dis; 2001 Jun; 189(6):377-83. PubMed ID: 11434638
[TBL] [Abstract][Full Text] [Related]
3. From conventional to atypical antipsychotics and back: dynamic processes in the diffusion of new medications.
Leslie DL; Rosenheck RA
Am J Psychiatry; 2002 Sep; 159(9):1534-40. PubMed ID: 12202274
[TBL] [Abstract][Full Text] [Related]
4. Administrative prescription review procedures and use of atypical antipsychotic medications in the Department of Veterans Affairs.
Rosenheck R; Leslie D
Ment Health Serv Res; 2003 Sep; 5(3):149-53. PubMed ID: 15224448
[TBL] [Abstract][Full Text] [Related]
5. Association of co-morbidities with prescribing patterns and cost savings: olanzapine versus risperidone for schizophrenia.
Yu W; Ren XS; Lee AF; Herz L; Huang YH; Kazis LE
Pharmacoeconomics; 2006; 24(12):1233-48. PubMed ID: 17129077
[TBL] [Abstract][Full Text] [Related]
6. Effects of antipsychotic medication on psychiatric service utilization and cost.
Rothbard A; Murrin MR; Jordan N; Kuno E; McFarland BH; Stroup TS; Morrissey JP; Stiles PG; Boothroyd RA; Merwin E; Shern DL
J Ment Health Policy Econ; 2005 Jun; 8(2):83-93. PubMed ID: 15998980
[TBL] [Abstract][Full Text] [Related]
7. Antipsychotic medication use patterns and associated costs of care for individuals with schizophrenia.
Loosbrock DL; Zhao Z; Johnstone BM; Morris LS
J Ment Health Policy Econ; 2003 Jun; 6(2):67-75. PubMed ID: 14578539
[TBL] [Abstract][Full Text] [Related]
8. Clinicians' reasons for antipsychotic coprescribing.
Sernyak MJ; Rosenheck R
J Clin Psychiatry; 2004 Dec; 65(12):1597-600. PubMed ID: 15641863
[TBL] [Abstract][Full Text] [Related]
9. Healthcare utilization and costs of Veterans Health Administration patients with schizophrenia treated with paliperidone palmitate long-acting injection or oral atypical antipsychotics.
Baser O; Xie L; Pesa J; Durkin M
J Med Econ; 2015 May; 18(5):357-65. PubMed ID: 25525771
[TBL] [Abstract][Full Text] [Related]
10. Outpatient antipsychotic treatment and inpatient costs of schizophrenia.
Marcus SC; Olfson M
Schizophr Bull; 2008 Jan; 34(1):173-80. PubMed ID: 17578893
[TBL] [Abstract][Full Text] [Related]
11. Benchmarking the quality of schizophrenia pharmacotherapy: a comparison of the Department of Veterans Affairs and the private sector.
Leslie DL; Rosenheck RA
J Ment Health Policy Econ; 2003 Sep; 6(3):113-21. PubMed ID: 14646004
[TBL] [Abstract][Full Text] [Related]
12. Treatment Patterns, Health Care Resource Utilization, and Spending in Medicaid Beneficiaries Initiating Second-generation Long-acting Injectable Agents Versus Oral Atypical Antipsychotics.
Pilon D; Tandon N; Lafeuille MH; Kamstra R; Emond B; Lefebvre P; Joshi K
Clin Ther; 2017 Oct; 39(10):1972-1985.e2. PubMed ID: 28919292
[TBL] [Abstract][Full Text] [Related]
13. Costs in the Treatment of Schizophrenia in Adults Receiving Atypical Antipsychotics: An 11-Year Cohort in Brazil.
Barbosa WB; Costa JO; de Lemos LLP; Gomes RM; de Oliveira HN; Ruas CM; Acurcio FA; Barbui C; Bennie M; Godman B; Guerra AA
Appl Health Econ Health Policy; 2018 Oct; 16(5):697-709. PubMed ID: 30051254
[TBL] [Abstract][Full Text] [Related]
14. Utilizing VA information technology to develop psychiatric resident prescription profiles.
Rohrbaugh R; Federman DG; Borysiuk L; Sernyak M
Acad Psychiatry; 2009; 33(1):27-30. PubMed ID: 19349439
[TBL] [Abstract][Full Text] [Related]
15. Off-label use of antipsychotic medications in the department of Veterans Affairs health care system.
Leslie DL; Mohamed S; Rosenheck RA
Psychiatr Serv; 2009 Sep; 60(9):1175-81. PubMed ID: 19723731
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia : a 12- and 24-month follow-up from the e-STAR database in Spain.
Olivares JM; Rodriguez-Martinez A; Burón JA; Alonso-Escolano D; Rodriguez-Morales A;
Appl Health Econ Health Policy; 2008; 6(1):41-53. PubMed ID: 18774869
[TBL] [Abstract][Full Text] [Related]
17. The effect of an Rx-to-OTC switch on medication prescribing patterns and utilization of physician services: the case of vaginal antifungal products.
Gurwitz JH; McLaughlin TJ; Fish LS
Health Serv Res; 1995 Dec; 30(5):672-85. PubMed ID: 8537226
[TBL] [Abstract][Full Text] [Related]
18. Use of system-wide outcomes monitoring data to compare the effectiveness of atypical neuroleptic medications.
Sernyak MJ; Leslie D; Rosenheck R
Am J Psychiatry; 2003 Feb; 160(2):310-5. PubMed ID: 12562578
[TBL] [Abstract][Full Text] [Related]
19. Use of risperidone and olanzapine in outpatient clinics at six Veterans Affairs hospitals.
Voris JC; Glazer WM
Psychiatr Serv; 1999 Feb; 50(2):163-4, 168. PubMed ID: 10030472
[No Abstract] [Full Text] [Related]
20. Aligning clinical practice to PTSD treatment guidelines: medication prescribing by provider type.
Abrams TE; Lund BC; Bernardy NC; Friedman MJ
Psychiatr Serv; 2013 Feb; 64(2):142-8. PubMed ID: 23474508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
